Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, Olubanke, Lewis, Gabriella, Lobo, Maria, Whiskey, Eromona, Shergill, Sukhi S. (2022) Vortioxetine as adjunctive therapy in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 12 . Article Number 2045125322. ISSN 2045-1261. (doi:10.1177/20451253221110014) (KAR id:95816)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
|
|
Download this file (PDF/849kB) |
![]() |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1177/20451253221110014 |
Abstract
Background: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. Objectives: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis. Design: This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust. Methods: Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression – Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months. Results: Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder–prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment. Conclusion: Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1177/20451253221110014 |
Additional information: | ** From Crossref journal articles via Jisc Publications Router ** History: epub 05-07-2022. |
Uncontrolled keywords: | Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Psychology (miscellaneous) |
Subjects: | R Medicine |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Funders: | NIHR Imperial Biomedical Research Centre (https://ror.org/01kmhx639) |
SWORD Depositor: | JISC Publications Router |
Depositing User: | JISC Publications Router |
Date Deposited: | 22 Nov 2022 15:08 UTC |
Last Modified: | 04 Mar 2024 16:37 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/95816 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):